Zura Bio Reports 2025 Results, Extends Cash Runway Outlook

Zura Bio ( (ZURA) ) just unveiled an update.

On March 19, 2026, Zura Bio reported its full-year 2025 results, highlighting progress in two ongoing Phase 2 trials of tibulizumab in hidradenitis suppurativa and systemic sclerosis, with HS topline data expected in late 2026 and SSc data in the first half of 2027. During 2025, the company increased R&D spending to $42.1 million, widened its net loss to $68.7 million, and ended the year with $109.4 million in cash and cash equivalents, while a $144 million public offering completed in February 2026, combined with its year-end cash, is expected to fund operations through at least the end of 2028, underpinned by new leadership appointments including CEO Sandeep Kulkarni and two new board members.

Zura also expanded enrollment in its Phase 2 TibuSHIELD trial in hidradenitis suppurativa to 225 participants to enhance statistical power, reinforcing its commitment to the tibulizumab program as the main value driver. The company’s balance sheet strengthening, alongside rising operating expenses and growing accumulated deficit, underscores an intensifying investment phase that could be pivotal for its positioning in the competitive autoimmune and inflammatory disease space, should upcoming clinical readouts support its differentiated mechanism of action.

The most recent analyst rating on (ZURA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.

Spark’s Take on ZURA Stock

According to Spark, TipRanks’ AI Analyst, ZURA is a Neutral.

Score is held back primarily by weak financial performance (pre-revenue, widening losses, and significant cash burn), partially offset by strong technical momentum and positive corporate updates supporting clinical progress and a stated funding runway through 2027. Valuation signals remain constrained by unprofitability and lack of dividend data.

To see Spark’s full report on ZURA stock, click here.

More about Zura Bio

Zura Bio Limited, based in Henderson, Nevada, is a clinical-stage biotechnology company focused on developing novel, differentiated medicines for serious and debilitating autoimmune and inflammatory diseases. Its lead asset is tibulizumab, a potential first- and only-in-class bispecific antibody targeting the interleukin-17 and B-cell activating factor pathways, alongside additional clinical-stage candidates crebankitug and torudokimab under strategic review.

Average Trading Volume: 688,815

Technical Sentiment Signal: Buy

Current Market Cap: $516.5M

Find detailed analytics on ZURA stock on TipRanks’ Stock Analysis page.